Round-up of the year's top SRUK News stories

To close out the decade, we shared our 19 most popular stories from 2019, building up to our most read piece of the year.

To close out the decade, we shared our 19 most popular stories from 2019, building up to our most read piece of the year.

While some of you will have read these stories already, we'd really appreciate it if you could share your favourites to help us spread the word about scleroderma, and empower everyone affected by scleroderma and Raynaud's to feel confident in managing their condition.

19. "Scleroderma and my grandmother…

the hidden condition"

by Dontaira Terrell

18. "Is Botox an option for Raynaud's?"



17. "My fear of cold"

Sara Szigeti's story


16. "The role of the lymphatic system

in scleroderma"


15. "Hannah's story of localised

scleroderma"


14. "Research into gut involvement in

systemic sclerosis"


13. "Can herbal medicine help Raynaud's

phenomenon symptoms"


12. "Sylvia story of using diet and exercise

to thrive with scleroderma"


11. "Stem cell transplants may be the next

new therapy for scleroderma"


10. "A novel study to detect early

scleroderma symptoms has been funded

by SRUK"

9. "Oral and dental involvement in

scleroderma: what happens and how

it can be managed"

8. "Can lung fibrosis be stopped?"



7. "Why early detection of scleroderma

matters"


6. "6 tips for self-management"



5. "A guide to Iloprost treatment"



4. "Understanding vascular involvement

in systemic sclerosis"


3. "Ex-professional footballer Travis Munn

talks about his cutting edge treatment"


2. "The impact of Raynaud's phenomenon

on mental health"


1. "New study suggests low vitamin D

levels linked to scleroderma"


Thanks for reading, and supporting us over the past year. Please let us know if there is a story you think we should be covering in 2020, or share your story with us to help us raise awareness.

If you are interested in supporting our work, then please donate today. We rely on the generosity of our community to continue to support groundbreaking research into both scleroderma and Raynaud's.